 |
|
|
| | | | | | Dear colleagues,
| | | | | | | | The 12ᵗʰ International Symposium on Hodgkin Lymphoma (ISHL12) will take place in Cologne, Germany, between October 24 and 26, 2020.
| | | | | | | | ISHL12 will cover the whole spectrum of research related to Hodgkin Lymphoma (HL).
| | | | | |
|
| | | | | | Emerging Concepts
in Early Stages | | | | | | | | During this three-day conference, an additional focus will be patients with early stage disease. Balancing toxicity and treatment intensity is an ongoing quest in these patients.
| | | | | | | | Recent phase III trials reported a significant loss of tumor control with omission of radiotherapy in PET-negative early-stage favorable patients (RAPID, H10F, HD16). In patients with early-stage unfavorable disease, intensification of systemic therapy in interim PET-positive patients results in improved outcomes (H10U), while data regarding consolidative RT are more heterogeneous (RAPID, H10U).
| | | | | | | | The large randomized GHSG HD17 trial is nearing its final analysis and results will shed light on the possibility to omit RT after intensified systemic therapy. In addition, current trials are investigating systemic therapies incorporating novel agents such as brentuximab vedotin or anti-PD1 antibodies and results including correlative studies are eagerly awaited.
| | | | | | | | Taken together, these ongoing efforts are likely to shape the future therapy of early-stage Hodgkin Lymphoma which will be discussed at ISHL12 in detail.
| | | | | |
|
|
|
|
|
